-
Posted by
Two Blokes Apr 17 -
Filed in
Stock
-
3 views
Immunome's unique human immune memory-based discovery engine and strategic pipeline expansion in oncology present a compelling investment opportunity, especially post-merger with Morphimmune. The company's strong financial position, with a cash runway extending through 2027, supports ongoing clinical development and potential market entry for key assets. Lead assets IM-1021 (ROR1 ADC) and IM-3050 (FAP RLT) entering Phase 1 trials, alongside varegacestat's Phase 3 progress, offer multiple near-term catalysts.
